Novartis acquires EBEWE's generic injectables business for $1.2 billion
This article was originally published in Scrip
Executive Summary
Novartis is to acquire EBEWE Pharma's generic injectables business for €925 million ($1.2 billion) in cash to strengthen its generics business Sandoz.